Catalyst Crew acquires AI healthcare IP and Venezuelan subsidiary from CEO in related-party transactions

LataMed AI Corp.

Acquired AI healthcare analytics IP (CardioAI, PulmoAI, NeuroAI) from CEO via APA dated Feb 17, 2026.
Acquired 100% of Inversiones Long 33, C.A. from CEO on March 23, 2026; now wholly-owned subsidiary.
IP formally assigned to subsidiary on April 7, 2026 as internal reorganization; no additional consideration.
Press releases issued March-April 2026 announcing CardioAI, PulmoAI, NeuroAI platforms and operating structure.

item 1.01 item 2.01 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001477932-26-002171
form_type: 8-K
ticker: CCTC
cik: 0001477960
company_name: LataMed AI Corp.
filed_at: 2026-04-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.340551+00:00
generated_at: 2026-05-15T06:33:43.918079+00:00
sec_items: ["1.01", "2.01", "7.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001477932-26-002171
json_url: https://secwatch.observer/filing/0001477932-26-002171.json
markdown_url: https://secwatch.observer/filing/0001477932-26-002171.md
text_url: https://secwatch.observer/filing/0001477932-26-002171.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1477960/000147793226002171/0001477932-26-002171-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1477960/000147793226002171/cctc_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001477932-26-002171

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.